Non-coding RNA in drug resistance of hepatocellular carcinoma | Zendy

Bisha Ding | Zendy; Weiyang Lou | Zendy; Liang Xu | Zendy; Weimin Fan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Non-coding RNA in drug resistance of hepatocellular carcinoma

Author(s) -

Bisha Ding,

Weiyang Lou,

Liang Xu,

Weimin Fan

Publication year - 2018

Publication title -

bioscience reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.938

H-Index - 77

eISSN - 1573-4935

pISSN - 0144-8463

DOI - 10.1042/bsr20180915

Subject(s) - hepatocellular carcinoma , microrna , long non coding rna , drug resistance , circular rna , rna , non coding rna , biology , cancer research , drug , medicine , bioinformatics , computational biology , gene , genetics , pharmacology

Hepatocellular carcinoma (HCC) has been one of the most highly lethal cancers. The acquisition of drug resistance accounts for the majority of poor effects of chemotherapy in HCC. Non-coding RNAs (ncRNAs) including miRNAs, long ncRNAs (lncRNAs), and circular RNA (circRNA) have been well-documented to participate in cancer occurrence and progression. Recently, multiple studies have highlighted the key roles of ncRNAs in chemoresistance of HCC. In addition, accumulating evidence has demonstrated that they can serve as biomarkers in diagnosis, treatment, and prognosis of HCC. In this review, we first overviewed up-to-date findings regarding miRNA and lncRNA in drug resistance of HCC, then summarized specific mechanisms that they modulate chemoresistance of HCC, and finally discussed their potential clinical application in overcoming the obstacle of HCC chemoresistance in the future.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research